Date: 27th July, 2022

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Re-classification of Dividend

Ref.: Intimation of Board Meeting dated 20th July, 2022 to consider Unaudited Financial Results for the quarter ended 30th June, 2022

With reference to the captioned matter and in continuation to the above referred intimation, the exchange is hereby informed that the Board of Directors of the Company at their meeting scheduled to be held on 4th August, 2022 shall also consider and approve re-classification of the final dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Charandeep Singh Saluja
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED
REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123